An updated patent review of IDO1 inhibitors for cancer (2018–2022)
Authors:
- 2 November 2022
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 32 (11) , 1145-1159
Abstract
Indoleamine 2,3-dioxygenase 1 (IDO1) is highly related to the immune evasion of a wide range of malignancies due to its role in the immune suppression caused by the depletion of tryptophan (Trp) an...Keywords
Funding Information
- Fundamental Research Funds for the Central Universities (2022CDJXY-025)
This publication has 34 references indexed in Scilit:
- IDO1 in cancer: a Gemini of immune checkpointsCellular & Molecular Immunology, 2018
- Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole ScaffoldACS Medicinal Chemistry Letters, 2018
- Discovery of IDO1 Inhibitors: From Bench to BedsideCancer Research, 2017
- Identification of new shikonin derivatives as STAT3 inhibitorsBiochemical Pharmacology, 2017
- Structural insights into substrate and inhibitor binding sites in human indoleamine 2,3-dioxygenase 1Nature Communications, 2017
- Discovery of imidazoleisoindole derivatives as potent IDO1 inhibitors: Design, synthesis, biological evaluation and computational studiesEuropean Journal of Medicinal Chemistry, 2017
- Important Hydrogen Bond Networks in Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Design Revealed by Crystal Structures of Imidazoleisoindole Derivatives with IDO1Journal of Medicinal Chemistry, 2015
- Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease modelsCell Death & Differentiation, 2012
- Cancer immunotherapy comes of ageNature, 2011
- Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenaseNature Medicine, 2003